Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.36 |
| ▸ | MAPT | P10636 | 6/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 3/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | NOS2 | P35228 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | SIRT1 | Q96EB6 | 2/20 | 0.34 |
| ▸ | HTR2B | P41595 | 2/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.33 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.33 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrazine SCHEMBL27885781 | 0.85 | ALDH1A1 (0.43) | LMNATSHRKMT2AMAPTKDM4E | |
| SCHEMBL3830913 | 0.85 | ALDH1A1 (0.45) | LMNATSHRKMT2AMAPTKDM4E | |
| SCHEMBL16772300 | 0.83 | MTNR1A (0.38) | LMNATSHRKMT2AMAPTKDM4E | |
| Hydrochloric Acid SCHEMBL9046996 | 0.83 | ALDH1A1 (0.44) | LMNATSHRKMT2AMAPTKDM4E | |
| SCHEMBL1071512 | 0.82 | MAPT (0.50) | LMNATSHRKMT2AMAPTKDM4E | |
| SCHEMBL8566125 | 0.80 | BACE1 (0.39) | LMNATSHRMAPTKDM4EALDH1A1 | |
| SCHEMBL8566128 | 0.80 | BACE1 (0.39) | LMNATSHRMAPTKDM4EALDH1A1 | |
| SCHEMBL8566129 | 0.80 | BACE1 (0.39) | LMNATSHRMAPTKDM4EALDH1A1 | |
| SCHEMBL859610 | 0.77 | KCNH2 (0.44) | ALDH1A1SIRT1KCNH2MTNR1AMTNR1B | |
| SCHEMBL29892593 | 0.77 | KCNH2 (0.44) | ALDH1A1SIRT1KCNH2MTNR1AMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101384172-A | Solid forms of N- [2, 4-bis (1, 1-dimethylethyl) -5-hydroxyphenyl ] -1, 4-dihydro-4-oxoquinoline-3-carboxamide | VERTEX PHARMA (US) | 2009-03-11 | — | — | CN | claimed |
| JP-2002522388-A | — | — | 2002-07-23 | — | — | JP | claimed |
| EP-1107759-A1 | PYRIDINONES FOR THE TREATMENT OF SEXUAL DYSFUNCTION | Basf Corporation (US) | 2001-06-20 | — | — | EP | claimed |
| WO-2000007595-A1 | PYRIDINONES FOR THE TREATMENT OF SEXUAL DYSFUNCTION | BASF CORPORATION (US) | 2000-02-17 | — | — | WO | claimed |
| US-20260034064-A1 | COMPOSITIONS FOR THE TREATMENT OF CFTR-MEDIATED DISEASES | VERTEX PHARMA (US) | 2026-02-05 | — | — | US | disclosed |
| US-12458635-B2 | Pharmaceutical composition and administrations thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-11-04 | — | — | US | disclosed |
| US-20250255819-A1 | PHARMACEUTICAL COMPOSITION AND ADMINISTRATIONS THEREOF | VERTEX PHARMA (US) | 2025-08-14 | — | — | US | disclosed |
| US-12214083-B2 | Pharmaceutical composition and administrations thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-02-04 | — | — | US | disclosed |
| US-20240156738-A1 | PHARMACEUTICAL COMPOSITION AND ADMINISTRATIONS THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2024-05-16 | — | — | US | disclosed |
| US-11752106-B2 | Pharmaceutical composition and administrations thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-09-12 | — | — | US | disclosed |
| US-20230210839-A1 | PHARMACEUTICAL COMPOSITION AND ADMINISTRATIONS THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-07-06 | — | — | US | disclosed |
| US-11564916-B2 | Pharmaceutical composition and administrations thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-01-31 | — | — | US | disclosed |
| US-20120064157-A1 | PHARMACEUTICAL COMPOSITION AND ADMINISTRATIONS THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-03-15 | — | — | US | disclosed |
| WO-2011019413-A1 | PHARMACEUTICAL COMPOSITION AND ADMINISTRATIONS THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-02-17 | — | — | WO | disclosed |
| US-20100256184-A1 | PHARMACEUTICAL COMPOSITION AND ADMINISTRATIONS THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-10-07 | — | — | US | disclosed |
| US-20100074949-A1 | Pharmaceutical composition and administration thereof | VERTEX PHARMACEUTICALS INCORPORATED | 2010-03-25 | — | — | US | disclosed |
| CN-101384172-A | Solid forms of N- [2, 4-bis (1, 1-dimethylethyl) -5-hydroxyphenyl ] -1, 4-dihydro-4-oxoquinoline-3-carboxamide | VERTEX PHARMA (US) | 2009-03-11 | — | — | CN | disclosed |
| EP-1107759-A1 | PYRIDINONES FOR THE TREATMENT OF SEXUAL DYSFUNCTION | Basf Corporation (US) | 2001-06-20 | — | — | EP | disclosed |
| WO-2000007595-A1 | PYRIDINONES FOR THE TREATMENT OF SEXUAL DYSFUNCTION | BASF CORPORATION (US) | 2000-02-17 | — | — | WO | disclosed |
| US-5096901-A | PHARMACOLOGICALLY ACTIVE AMIDES AND ESTERS CONTAINING AN AZABICYCLOALKANE MOIETY | JOHN WYETH & BROTHER LIMITED (GB) | 1992-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12214083-B2 | Pharmaceutical composition and administrations thereof | CFTR, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, KCNQ5 | LMNA 2477/4885TSHR 4717/4885KMT2A 595/4885 |
| US-20100256184-A1 | PHARMACEUTICAL COMPOSITION AND ADMINISTRATIONS THEREOF | CYP3A5, CYP4B1, CYP3A4 | LMNA 2332/4885TSHR 4765/4885KMT2A 523/4885 |
| US-12458635-B2 | Pharmaceutical composition and administrations thereof | CYP3A5, CYP4B1, CYP3A4 | LMNA 2332/4885TSHR 4765/4885KMT2A 523/4885 |
| US-20240156738-A1 | PHARMACEUTICAL COMPOSITION AND ADMINISTRATIONS THEREOF | CFTR, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, KCNQ5 | LMNA 2477/4885TSHR 4717/4885KMT2A 595/4885 |
| US-20100074949-A1 | Pharmaceutical composition and administration thereof | CYP3A5, CYP3A4, CYP4B1 | LMNA 1865/4885TSHR 4754/4885KMT2A 434/4885 |
| US-11752106-B2 | Pharmaceutical composition and administrations thereof | CFTR, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, KCNQ5 | LMNA 2477/4885TSHR 4717/4885KMT2A 595/4885 |
| US-20230210839-A1 | PHARMACEUTICAL COMPOSITION AND ADMINISTRATIONS THEREOF | CYP3A5, CYP4B1, CYP3A4 | LMNA 2332/4885TSHR 4765/4885KMT2A 523/4885 |
| US-20250255819-A1 | PHARMACEUTICAL COMPOSITION AND ADMINISTRATIONS THEREOF | CFTR, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, KCNQ5 | LMNA 2477/4885TSHR 4717/4885KMT2A 595/4885 |
| US-20260034064-A1 | COMPOSITIONS FOR THE TREATMENT OF CFTR-MEDIATED DISEASES | CFTR, ABCC2, ABCC8 | LMNA 2240/4885TSHR 2037/4885KMT2A 1937/4885 |
| US-20120064157-A1 | PHARMACEUTICAL COMPOSITION AND ADMINISTRATIONS THEREOF | CFTR, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, KCNQ5 | LMNA 2446/4885TSHR 4698/4885KMT2A 564/4885 |
| US-11564916-B2 | Pharmaceutical composition and administrations thereof | CYP3A5, CYP4B1, CYP3A4 | LMNA 2332/4885TSHR 4765/4885KMT2A 523/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.